February 2026
Ready for HCV Test-to-Treat?
Only one in three people with hepatitis C in the US receive timely treatment. From same-day point-of-care hepatitis C diagnosis to rapid treatment initiation, check out NVHR’s new resource to learn about opportunities to increase the accessibility, availability, and affordability of hepatitis C testing and treatment for all.
You can read and download the new resource at this link.
“In the United States (U.S.), only one in three people with hepatitis C (HCV) receive timely treatment, defined as HCV treatment within 12 months following diagnosis, despite cure rates in the range of 95% for treatment with direct-acting antivirals (DAAs). People with diagnosed but untreated HCV are at risk of morbidity and disease progression, transmission, and loss to follow up. Further progress towards eliminating HCV as a public health threat in the U.S. requires expanding testing and reducing gaps between diagnosis and treatment. The availability of point-of-care (POC) diagnostics, along with consideration to policy opportunities to address barriers to timely treatment initiation, hold promise for shortening the window between diagnosis and treatment, reducing loss to follow up, and achieving long-term health benefits and cost savings from curing a greater proportion of the 2.4 million people in the U.S. with chronic HCV.”
For further information, please reach out to the NVHR team at info@nvhr.org